191 related articles for article (PubMed ID: 28495239)
21. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
[TBL] [Abstract][Full Text] [Related]
28. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Hynninen J; Lavonius M; Oksa S; Grénman S; Carpén O; Auranen A
Gynecol Oncol; 2013 Feb; 128(2):229-32. PubMed ID: 23142076
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.
Gemer O; Oustinov N; Gdalevich M; Dubnik S; Levy R; Yachnin A; Lavie O; Ben Baruch N; Ben Arie A
Tumori; 2013; 99(2):257-60. PubMed ID: 23748823
[TBL] [Abstract][Full Text] [Related]
30. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
31. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
[TBL] [Abstract][Full Text] [Related]
32. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
Chern JY; Curtin JP
Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
[TBL] [Abstract][Full Text] [Related]
33. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Zhu J; Wang H; Liu CC; Lu Y; Tang H
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
[TBL] [Abstract][Full Text] [Related]
34. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.
Chao KC; Chen YJ; Juang CM; Lau HY; Wen KC; Sung PL; Fang FY; Twu NF; Yen MS
Taiwan J Obstet Gynecol; 2013 Mar; 52(1):81-4. PubMed ID: 23548224
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
[TBL] [Abstract][Full Text] [Related]
37. [Tumor size and prognosis for patients with epithelial ovarian carcinoma at early stage].
Lazarov N; Lazarov L; Lazarov S
Akush Ginekol (Sofiia); 2013; 52(4):10-2. PubMed ID: 24283071
[TBL] [Abstract][Full Text] [Related]
38. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
[TBL] [Abstract][Full Text] [Related]
40. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
